Biotech

All Articles

Sanofi's tolebrutinib falls short 2 of 3 late-stage MS trials

.Sanofi is still set on taking its a number of sclerosis (MS) med tolebrutinib to the FDA, managers ...

Galapagos' stock up as fund shows intent to mold its evolution

.Galapagos is coming under added tension from financiers. Having actually constructed a 9.9% risk in...

Cell- focused Sana scoops very first CSO-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of substantial leadership hirings, firings a...

Allist pays off Jacobio $21M, landing role in Mandarin KRAS nationality

.Shanghai Allist Pharmaceuticals has actually acquired on its own a starring character in China's KR...

ReNeuron leaving goal substitution after missing out on fundraising objective

.ReNeuron has joined the lengthy checklist of biotechs to leave London's intention stock market. The...

MBX files for IPO to take opposition to Ascendis into phase 3

.MBX Biosciences has actually included in the recent flurry of IPO filings. The biotech, which submi...

FDA expands probing right into Lykos' MDMA trials: WSJ

.For Lykos Therapies and also the company's prospective MDMA-assisted therapy for post-traumatic str...

Gene publisher Tome giving up 131 laborers

.Simply times after genetics publisher Tome Biosciences introduced concealed functional cuts, a more...

Repare lays off 25% of personnel as biotech stops preclinical R&ampD

.Repare Therapeutics is laying off a fourth of its own labor force as the oncology biotech lessen it...

J &amp J declare FDA authorization of $6.5 B autoimmune medicine

.Johnson &amp Johnson has gotten one more action toward understanding a yield on its own $6.5 billio...